Notable Quacks who promote(d) orthomolecular medicine and vitamin therapy for degenerative conditions.
en.wikipedia.org
Where quantum theory was born
"Pauling had first been exposed to the concept of quantum theory while he was studying at Oregon Agricultural College. "
He also had something to do with the Henney Kilowatt pictured below. (an early electric car)
Performance
The 1959 models all ran on a 36-volt system of 18 sequential two-volt batteries. The 36-volt cars had a top speed of 40 mph and could run approximately 40 miles on a full charge. After the 36-volt system was realized to be impractical, the Kilowatt drivetrain was redesigned by Eureka Williams as a 72-volt system for the 1960 model year. It employed 12 sequential six-volt batteries. The 72-volt models were much more practical than the 1959 36-volt models. The 1960 Kilowatt boasted a top speed of nearly 60 mph with a range of over 60 miles on a single charge.
According to a French Renault Dauphine enthusiast website, Renault sold 100 rolling chassis to Henney Coachworks for the project, but only 47 of the cars were ever built. A March 20, 1967 article in U.S. News & World Report states that 35 of the Henney Kilowatts were purchased by electric utilities in the United States. Company records show that there were 24 cars sold as 1959 models and 8 Kilowatts sold as 1960 models. It is unclear when the other 15 cars were produced, but records show that some of them may have been sold as 1961 or possibly 1962 models. A total of eight cars were produced for the 1960 model year, but none of them were sold to the public because of the high manufacturing costs for the 72-volt system. Instead, all eight 1960 models went to the electric cooperatives who funded the development of the Kilowatt. The company continued promoting the Kilowatt in 1961 with hopes of securing enough prepaid orders to finish the remaining chassis components that had already been purchased from Renault; few, if any, were sold in this manner.
************************************
Vitamin C, Cancer and heart Disease
Pauling's work on vitamin C in his later years generated controversy and was originally regarded by some adversaries in the field of medicine as outright quackery.[15] He was first introduced to the concept of high-dose vitamin C by biochemist Irwin Stone in 1966 and began taking several grams every day to prevent colds. Excited by the results, he researched the clinical literature and published "Vitamin C and the Common Cold" in 1970. He began a long clinical collaboration with the British cancer surgeon, Ewan Cameron,[16] in 1971 on the use of intravenous and oral vitamin C as cancer therapy for terminal patients. Cameron and Pauling wrote many technical papers and a popular book, "Cancer and Vitamin C", that discussed their observations. Three prospective, randomized, placebo-controlled trials were conducted by Moertel et al. at the Mayo Clinic; all three failed to prove a benefit for megadoses of vitamin C in cancer patients.[17] Pauling denounced Charles Moertel's conclusions and handling of the final study as "fraud and deliberate misrepresentation."[18][19] Pauling then published critiques of the second Mayo-Moertel cancer trial's flaws over several years as he was able to slowly unearth some of the trial's undisclosed details.[20] However, the wave of adverse publicity generated by Moertel and the media effectively undercut Pauling's credibility and his vitamin C work for a generation,[21] the oncological mainstream continued with other avenues of treatment.[22] Always precariously perched since his molecular biologically inspired crusade to stop atmospheric nuclear testing in the 1950s,[23] the 1985 Mayo-Moertel confrontation left Pauling isolated from his institutional funding sources, academic support and a bemused public. He later collaborated with the Canadian physician, Abram Hoffer,[24] on a micronutrient regimen, including high-dose vitamin C, as adjunctive cancer therapy.
As of 2006, new evidence of high-dose Vitamin C efficacy was proposed by a Canadian group of researchers. These researchers observed longer-than expected survival times in three patients treated with high doses of intravenous Vitamin C.[25] The researchers are reportedly planning a new Phase I clinical trial [26] The selective toxicity of vitamin C for cancer cells has been demonstrated in-vitro (i.e., in a cell culture Petri dish), and was reported in 2005. [27] The combination of case-report data and preclinical information suggest biological plausibility and the possibility of clinical efficacy at the possible expense of critical toxicity at active doses; future clinical testing will ultimately determine the utility and safety of intravenous high-dose Vitamin C treatments for patients with cancer. Researchers released a paper demonstrating in-vitro vitamin C killing of cancer cells in The Proceedings of the National Academy of Sciences in 2006[28]. |
